

INDEX

A

- AKT. *See* PI3K/AKT cascade.
- Animal models, and oncogenesis of glioma, **1193–1214**
- molecular biology of, 1193–1197
 - cell cycle regulation, 1196–1197
 - growth factors and receptor tyrosine kinase, 1193–1195
 - signal transduction cascades, 1195–1196
 - mouse models of, 1197–1203
 - astrocytoma models, 1201–1202
 - effect of cell cycle deregulation, 1203
 - modeling techniques, 1197–1200
 - oligodendroglioma models, 1202–1203
 - preclinical trials in mouse models of, 1203–1206
 - PI3K-AKT cascade, 1205–1206
 - RAS/MAPK cascade, 1206
 - receptor tyrosine kinase inhibitors, 1203–1205
 - multimodality molecular imaging of tumors in, **1215–1248**
- Antibodies, neuronal, novel, in paraneoplastic limbic encephalitis, 1324–1325
- Astrocytoma, changing management of low-grade gliomas, **1249–1266**
- classification, 1250–1252
 - clinical presentation, 1252–1253
 - epidemiology and etiology, 1250
 - future trends, 1261–1262
 - natural history, 1255
 - prognostic features, 1255–1256
 - radiologic features, 1253–1255
 - therapy, 1256–1261
 - chemotherapy, 1260–1261
 - radiotherapy, 1257–1260
 - surgery, 1256–1257
 - mouse models of, 1201–1202

Autologous stem cell transplant, for primary central nervous system lymphoma, 1279–1280

B

- Biologic agents, for brain metastases, 1293
- Biology. *See also* Molecular biology.
- of brain metastases, 1287–1289
 - of gliomas, changing paradigm of, **1171–1191**
 - discussion, 1185–1190
 - development of resistance, 1187–1190
 - effect of tumor genetic evolution, 1185–1186
 - heterogeneity, general and regional, 1187
 - local *versus* diffuse disease, 1186–1187
 - pathogenesis, 1171–1176
 - prognosis, 1176–1178
 - treatment, 1178–1185
- Blood-brain barrier disruption, in treatment of brain metastases, 1293–1294
- Brain edema, in brain tumor patients, supportive care for, 1337–1347
- blood-brain barrier and edemagenesis, 1337–1340
 - classification, 1337
 - emergency therapy for increased intracranial pressure due to, 1346–1347
 - steroid therapy, 1341–1346
- Brain metastases, chemotherapy and treatment of, **1287–1295**
- at recurrence, 1291–1293
 - biologic agents, 1293
 - biology of, 1287–1289
 - blood-brain barrier disruption, 1293–1294
 - concurrent chemoradiotherapy and radiosensitizers, 1289–1291
 - initial chemotherapy, 1289

Note: Page numbers of article titles are in **boldface** type.

- Brain metastases (*continued*)
- metastatic epidural spinal cord compression, clinical approach, **1297–1305**
 - surgical approach, **1307–1317**
- Brain tumors, 1171–1398
- brain metastases, chemotherapy and treatment of, **1287–1295**
 - metastatic epidural spinal cord compression, clinical approach, **1297–1305**
 - surgical approach, **1307–1317**
 - central nervous system toxicity from therapies for, **1377–1398**
 - chemotherapy, 1387–1395
 - radiation therapy, 1377–1387
 - cognitive functions in patients with, **1363–1376**
 - neuropsychologic assessment, 1364
 - tumor and treatment effects on, 1364–1372
 - chemotherapy alone or combined with radiotherapy, 1369–1372
 - conformal radiotherapy, 1368–1369
 - treatment-related neurotoxicity, 1365–1368
 - tumor and surgery, 1364–1365
 - gliomas, biology of, changing paradigm of, **1171–1191**
 - discussion, 1185–1190
 - pathogenesis, 1171–1176
 - prognosis, 1176–1178
 - treatment, 1178–1185
 - low-grade, changing management of astrocytomas and oligodendrogliomas, **1249–1266**
 - classification, 1250–1252
 - clinical presentation, 1252–1253
 - epidemiology and etiology, 1250
 - future trends, 1261–1262
 - natural history, 1255
 - prognostic features, 1255–1256
 - radiologic features, 1253–1255
 - therapy, 1256–1261
 - oncogenesis and animal models of formation of, **1193–1214**
 - molecular biology of, 1193–1197
 - mouse models of, 1197–1203
 - preclinical trials in mouse models of, 1203–1206
- limbic encephalitis, **1319–1335**
- clinical-immunologic phenotypes, 1325–1332
 - diagnostic dilemmas, 1324
 - historical remarks, 1320
 - novel neuronal antibodies, 1324–1325
 - recognizing the paraneoplastic etiology, 1321–1324
 - recognizing the syndrome, 1320–1321
- molecular imaging of, multimodality, **1215–1248**
- biomarker and direct imaging strategies, 1230–1233
 - imaging cell signaling pathways, 1234–1237
 - imaging oncogenesis in mouse models, 1233–1234
 - imaging tumor treatment, 1237–1241
 - reporter gene imaging, 1216–1230
- primary central nervous system lymphoma, **1267–1285**
- clinical presentation and diagnosis, 1269
 - epidemiology, 1267–1268
 - leptomeningeal lymphoma, 1278–1279
 - neuroimaging, 1269–1270
 - ocular lymphoma, 1279
 - pathogenesis, 1268
 - pathology, 1270
 - prognostic factors, 1271
 - staging evaluation, 1270–1271
 - treatment, 1271
 - autologous stem-cell transplant, 1279–1280
 - chemotherapy alone, 1277–1278
 - combined chemoradiotherapy and radiotherapy, 1277–1278
 - neurotoxicity related to, 1280
 - radiotherapy, 1272–1273
 - salvage therapy, 1280
 - survival trends after chemotherapy, 1281
- supportive care, **1337–1361**
- brain edema, 1337–1347
 - seizures, 1347–1349
 - venous thromboembolism, 1349–1353

Download English Version:

<https://daneshyari.com/en/article/3331909>

Download Persian Version:

<https://daneshyari.com/article/3331909>

[Daneshyari.com](https://daneshyari.com)